JP7079551B2 - ヒドロキシチロソールおよびボスウェリン酸を有する組成物 - Google Patents
ヒドロキシチロソールおよびボスウェリン酸を有する組成物 Download PDFInfo
- Publication number
- JP7079551B2 JP7079551B2 JP2019516976A JP2019516976A JP7079551B2 JP 7079551 B2 JP7079551 B2 JP 7079551B2 JP 2019516976 A JP2019516976 A JP 2019516976A JP 2019516976 A JP2019516976 A JP 2019516976A JP 7079551 B2 JP7079551 B2 JP 7079551B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxytyrosol
- composition
- keto
- acetyl
- boswellic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims (10)
- 一種かそれ以上の炎症メディエーターを原因とする結合組織の損傷を治療、修復または緩和するために構成された経口投与可能な組成物であって、これを必要とする対象動物の結合組織における炎症反応を防止又は低減する量でヒドロキシチロソールおよび3-O-アセチル-11-ケト-β-ボスウェリン酸が相乗的に作用する組み合わせであることを特徴とする組成物。
- 前記ヒドロキシチロソール源がオリーブ抽出物、オリーブの木から得られる生成物、又はオリーブの木から得られる副生物のうちの少なくとも一つであり、
前記3-O-アセチル-11-ケト-β-ボスウェリン酸源がBoswellia serrata抽出物である請求項1に記載の組成物。
- 哺乳類又は鳥類を対象として経口投与用に配合した請求項1に記載の組成物。
- 前記哺乳類をヒト、犬、猫、馬、駱駝または牛からなる群から選択する請求項3に記載の組成物。
- 前記ヒトを対象として経口投与用に配合した前記組成物が、体重1kg当たり約0.67mg~約2.70mgの量で3-O-アセチル-11-ケト-β-ボスウェリン酸を有し、前記犬を対象として経口投与用に配合した前記組成物が、体重1kg当たり約1.24mg~約4.98mgの量で3-O-アセチル-11-ケト-β-ボスウェリン酸を有する請求項4に記載の組成物。
- 前記ヒトを対象として経口投与用に配合した前記組成物が、体重1kg当たり約0.15mg~約2.50mgの量でヒドロキシチロソールを有し、前記犬を対象として経口投与用に配合した前記組成物が、体重1kg当たり約0.28mg~約4.60mgの量でヒドロキシチロソールを有する請求項4に記載の組成物。
- 前記ヒドロキシチロソールおよび前記3-O-アセチル-11-ケト-β-ボスウェリン酸が単独の組成物として共に前記対象動物に対し投与されるものである請求項1に記載の組成物。
- 前記ヒドロキシチロソールおよび前記3-O-アセチル-11-ケト-β-ボスウェリン酸が前記対象動物に対し個別に1時間以内に投与される請求項1に記載の組成物。
- 前記ヒドロキシチロソールおよび前記3-O-アセチル-11-ケト-β-ボスウェリン酸が前記対象動物に対し個別に30分以内に投与される請求項1に記載の組成物。
- 前記ヒドロキシチロソールおよび前記3-O-アセチル-11-ケト-β-ボスウェリン酸が前記対象動物に対し個別に5分以内に投与される請求項1に記載の組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022082301A JP7341596B2 (ja) | 2016-10-04 | 2022-05-19 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
JP2023137408A JP2023159387A (ja) | 2016-10-04 | 2023-08-25 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662403807P | 2016-10-04 | 2016-10-04 | |
US62/403,807 | 2016-10-04 | ||
PCT/US2017/028857 WO2018067200A1 (en) | 2016-10-04 | 2017-04-21 | Compositions comprising hydroxytyrosol and boswellic acid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022082301A Division JP7341596B2 (ja) | 2016-10-04 | 2022-05-19 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019529482A JP2019529482A (ja) | 2019-10-17 |
JP2019529482A5 JP2019529482A5 (ja) | 2020-05-28 |
JP7079551B2 true JP7079551B2 (ja) | 2022-06-02 |
Family
ID=58664857
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019516976A Active JP7079551B2 (ja) | 2016-10-04 | 2017-04-21 | ヒドロキシチロソールおよびボスウェリン酸を有する組成物 |
JP2022082301A Active JP7341596B2 (ja) | 2016-10-04 | 2022-05-19 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
JP2023137408A Pending JP2023159387A (ja) | 2016-10-04 | 2023-08-25 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022082301A Active JP7341596B2 (ja) | 2016-10-04 | 2022-05-19 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
JP2023137408A Pending JP2023159387A (ja) | 2016-10-04 | 2023-08-25 | 炎症メディエーターのレベルを低減するための組成物及び方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11241444B2 (ja) |
EP (1) | EP3522874A1 (ja) |
JP (3) | JP7079551B2 (ja) |
CN (1) | CN109789110A (ja) |
AU (2) | AU2017340126B2 (ja) |
CA (1) | CA3039233A1 (ja) |
WO (1) | WO2018067200A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7079551B2 (ja) | 2016-10-04 | 2022-06-02 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | ヒドロキシチロソールおよびボスウェリン酸を有する組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102451428A (zh) | 2010-10-14 | 2012-05-16 | 中国中医科学院广安门医院 | 可用于治疗类风湿关节炎的中药组合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358542B2 (en) | 1999-12-20 | 2002-03-19 | Usana, Inc. | Antioxidant compositions extracted from olives and olive by-products |
US7713569B2 (en) | 2000-09-01 | 2010-05-11 | Creagri, Inc. | Hydroxytyrosol-rich composition from olive vegetation water and method of use thereof |
WO2002018310A1 (en) | 2000-09-01 | 2002-03-07 | Creagri, Inc. | Method of obtaining a hydroxytyrosol-rich composition from vegetation water |
WO2003068171A2 (en) | 2002-02-13 | 2003-08-21 | Creagri, Inc. | Method and composition for treatment of inflammation and aids-associated neurological disorders |
US20030199581A1 (en) | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
EP1582512A1 (en) | 2004-03-31 | 2005-10-05 | Cognis IP Management GmbH | Process for obtaining hydroxytyrosol from olive leaves extracts |
EP1765761B1 (en) | 2004-06-18 | 2013-04-03 | Laila Nutraceuticals | Novel analogs of 3-o-acetyl-11-keto-beta-boswellic acid |
US20080300198A1 (en) * | 2004-08-09 | 2008-12-04 | Kathleen Matt | Olive Compositions and Methods for Treating Inflammatory Conditions |
WO2008006582A1 (en) | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases |
CN101516364B (zh) * | 2006-07-14 | 2011-12-28 | 帝斯曼知识产权资产管理有限公司 | 组合物及其用于治疗、共治疗或预防炎性病症的用途 |
JP2008120716A (ja) | 2006-11-10 | 2008-05-29 | Eisai Food Chemical Kk | 抗炎症剤 |
KR101682512B1 (ko) | 2008-09-15 | 2016-12-05 | 라일라 뉴트라슈티칼스 | 보스웰리아 세라타 추출물을 포함하는 상승적인 항-염증 조성물 |
CA2892375A1 (en) * | 2012-11-30 | 2014-06-05 | Darlene E. MCCORD | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
US10342802B2 (en) | 2016-10-04 | 2019-07-09 | Nutramax Laboratories, Inc. | Compositions comprising hydroxytyrosol and boswellic acid |
JP7079551B2 (ja) | 2016-10-04 | 2022-06-02 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | ヒドロキシチロソールおよびボスウェリン酸を有する組成物 |
-
2017
- 2017-04-21 JP JP2019516976A patent/JP7079551B2/ja active Active
- 2017-04-21 WO PCT/US2017/028857 patent/WO2018067200A1/en unknown
- 2017-04-21 AU AU2017340126A patent/AU2017340126B2/en active Active
- 2017-04-21 CA CA3039233A patent/CA3039233A1/en active Pending
- 2017-04-21 EP EP17720995.4A patent/EP3522874A1/en active Pending
- 2017-04-21 CN CN201780061735.7A patent/CN109789110A/zh active Pending
-
2020
- 2020-03-26 US US16/830,454 patent/US11241444B2/en active Active
-
2021
- 2021-12-22 US US17/559,571 patent/US11980624B2/en active Active
-
2022
- 2022-05-19 JP JP2022082301A patent/JP7341596B2/ja active Active
-
2023
- 2023-05-31 AU AU2023203427A patent/AU2023203427A1/en active Pending
- 2023-08-25 JP JP2023137408A patent/JP2023159387A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102451428A (zh) | 2010-10-14 | 2012-05-16 | 中国中医科学院广安门医院 | 可用于治疗类风湿关节炎的中药组合物 |
Non-Patent Citations (4)
Title |
---|
Cancer Res.,2009年,Vol.69,No.14,pp.5893-5900 |
Current Cancer Drug Targets,Vol.13,2013年,pp.625-639 |
Journal of Nutritional Biochemistry,Vol.26,2015年,pp.360-368 |
Molecules,2013年,Vol.18,pp.5265-5287 |
Also Published As
Publication number | Publication date |
---|---|
JP2022110125A (ja) | 2022-07-28 |
AU2017340126B2 (en) | 2023-03-02 |
US11980624B2 (en) | 2024-05-14 |
CN109789110A (zh) | 2019-05-21 |
AU2023203427A1 (en) | 2023-06-29 |
US20200222424A1 (en) | 2020-07-16 |
JP2019529482A (ja) | 2019-10-17 |
EP3522874A1 (en) | 2019-08-14 |
CA3039233A1 (en) | 2018-04-12 |
JP7341596B2 (ja) | 2023-09-11 |
JP2023159387A (ja) | 2023-10-31 |
AU2017340126A1 (en) | 2019-04-11 |
US11241444B2 (en) | 2022-02-08 |
US20220110946A1 (en) | 2022-04-14 |
WO2018067200A1 (en) | 2018-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jerosch | Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially Omega‐3 fatty acids | |
AU2008202916B2 (en) | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activty of cyclooxygenase-2 | |
JP2008519852A (ja) | シクロオキシゲナーゼ−2の発現及び/又は活性の相乗的阻害を示すクルクミノイド組成物 | |
D’Adamo et al. | Nutraceutical activity in osteoarthritis biology: a focus on the nutrigenomic role | |
US20200046681A1 (en) | Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration | |
JP2023159387A (ja) | 炎症メディエーターのレベルを低減するための組成物及び方法 | |
US10722524B2 (en) | Compositions comprising hydroxytyrosol and boswellic acid | |
Sukhikh et al. | Chondroprotection and molecular mechanism of action of phytonutraceuticals on osteoarthritis | |
US20110105611A1 (en) | Use of maslinic acid for the treatment of pathologies and their symptoms through the inhibition of cox-2 | |
US20090156551A1 (en) | Novel composition | |
TWI454271B (zh) | 一種用於治療骨關節炎的草藥組合物 | |
Ibrahim et al. | Curcumin A potential antagonist against paracetamol induced nephrotoxicity in rats. | |
US11426363B2 (en) | Compositions including cannabis and avocado/soybean unsaponifiables and methods of use | |
US20200384052A1 (en) | Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration | |
Araújo et al. | An Insight on the Biomedical Potential of Portuguese Propolis from Gerês. Foods 2022, 11, 3431 | |
Manimekalai et al. | Anti-inflammatory and anti-arthritic activity of some indigenous plants: A review | |
NZ618389B2 (en) | Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200414 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200414 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220426 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220519 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7079551 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |